Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05279027 · ClinicalTrials.gov registry record · Early Phase 1
Zr89 + PET Companion Trial
A Early Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT05279027: Completed Early Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT05279027 is a Early Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 6 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05279027, a Early Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Study of Zirconium Zr 89 Crefmirlimab Berdoxa PET/CT as an imaging biomarker for assessing an early response to therapy in patients with advanced melanoma on immunotherapy and hydroxychloroquine. This study is a companion study to the "LIMIT Melanoma Trial." Patients with melanoma who are potentially eligible for the LIMIT Melanoma Trial and have at least one site of measurable disease based on RECIST 1.1 are potentially eligible. Associations with progression-free survival (PFS) and overall survival (OS) will be tested.
Primary Outcome
Zirconium Zr 89 Crefmirlimab Berdoxa measured uptake \*(by standard uptake value) on Baseline and post-Treatment PET/CT scans in tumor lesions and lymphoid organs.
Interventions
- DRUG Zirconium Zr 89 Crefmirlimab Berdoxa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-03-08 |
| Est. Completion | 2025-05-06 |
| Phase | Early Phase 1 |
What the finished NCT05279027 record still lists
NCT05279027 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which Zirconium Zr 89 Crefmirlimab Berdoxa is the first listed.
NCT05279027 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05279027 about?
NCT05279027 is a clinical study titled "Zr89 + PET Companion Trial". Study of Zirconium Zr 89 Crefmirlimab Berdoxa PET/CT as an imaging biomarker for assessing an early response to therapy in patients with advanced melanoma on immunotherapy and hydroxychloroquine. This study is a companion study to the "LIMIT Melanoma Trial." Patients with melanoma who are potentiall...
What is the current status of trial NCT05279027?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2022-03-08. Estimated completion is 2025-05-06.
What interventions are being tested in trial NCT05279027?
The interventions under investigation include: Zirconium Zr 89 Crefmirlimab Berdoxa (DRUG).
Who is sponsoring clinical trial NCT05279027?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05279027's enrollment target sits among peer trials
6 1846th of 2000 higher than 114 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI